 |
|
Home | Medicis Pharmaceutic (MRX) Given “Neutral” Rating by Zacks Investment Research Analysts |
 |
Medicis Pharmaceutic (MRX) Given “Neutral” Rating by Zacks Investment Research Analysts
|
 |
- April 11, 2011
-
Equities research analysts at Zacks Investment Research reiterated a “neutral” rating on shares of Medicis Pharmaceutic (NYSE: MRX) in a research note to investors on Thursday. Separately, analysts at Deutsche Bank (NYSE: DB) reiterated a “buy” rating on shares of Medicis Pharmaceutic in a research note to investors on Thursday. They now have a $40.00 [...]This article (Medicis Pharmaceutic (MRX) Given “Neutral” Rating by Zacks Investment Research Analysts) was originally developed by and is property of American Banking News. Checkout American Banking News for up-to-date banking news and peer to peer lending news.
- Read more at:http://www.americanbankingnews.com/2011/04/11/medicis-pharmaceutic-mrx-given-neutral-rating-by-zacks-investment-research-analysts/
|
 |
|
 |
|
 |
